Colorectal Neoplasms
Conditions
Keywords
Metastatic Colorectal Cancer, 90Y, Liver Metastases, SIRT, Radioembolization, SIR-Spheres Microspheres
Brief summary
This real-world study tries to collect data reflecting routine use of SIR-Spheres in patients diagnosed with unresectable liver metastases from Metastatic Liver Tumors From Primary Colorectal Cancer (mCRC) refractory to or intolerant to chemotherapy, in order to assess clinical response in a real-world setting and further validate the safe and appropriate use of SIR-Spheres in China.
Detailed description
This is a post-market trial evaluating the efficacy and safety of SIR-Spheres® Y-90 resin microspheres for the treatment of unresectable metastatic liver tumors from primary colorectal cancer. Patients enrolled should already complete the infusion of SIR-Spheres® and data are about to be collected both retrospectively and prospectively. 200 patients are anticipated to be enrolled and followed up for up to 24 months.
Interventions
SIR-Spheres Y-90 resin microspheres are permanent implant and for single use only
Sponsors
GrandPharma (China) Co., Ltd.
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Obtained informed consent for patients to be follow-up prospectively 2. Age≥18 years old 3. Histologically or pathologically confirmed diagnosis of unresectable metastatic liver tumors from primary colorectal cancer and failed standard of care 4. Received SIR-Spheres®
Exclusion criteria
1. Special contraindications from package insert, which includes 1. Markedly abnormal liver function tests, such as total bilirubin \> 2.0 mg/dL or albumin \<3.0 g/dL 2. Portal vein thrombosis in the main trunk 3. Disseminated extrahepatic disease 4. Previous external beam radiation therapy to the liver 2. Women are lactating or pregnant during the study or plan to be pregnant during the study 3. Patients with mental illness or cognitive impairment 4. Per investigator, patients are non-adherent or reluctant to be followed up
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Liver-specific overall response rate (ORR) according to RECIST 1.1 | 24 months | Percentage of subjects with complete or partial responses to the liver as determined by the investigator according to liver-specific RECIST 1.1 criteria |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 1-yr OS | 12 months | The percentage of subjects treated with yttrium \[90Y\] resin microspheres who survived at 1 year. |
| Progression-free survival(PFS) assessed by the investigator | 24 months | Defined as the time from the date of treatment with the yttrium \[90Y\] resin microspheres to the time when disease progression or subject death from any cause during the study period was first determined by the investigator according to RECIST 1.1 criteria, whichever occurred first. |
| Liver-specific PFS assessed by the investigator | 24 months | Defined as the time from the date of treatment with yttrium \[90Y\] resin microspheres until the first time progression of liver disease or death of the subject from any cause during the study period was determined by the investigator according to liver-specific RECIST 1.1 criteria, whichever occurred first. |
| Overall survival (OS) | 24 months | From the day of treatment with yttrium \[90Y\] resin microspheres to the time of death due to any cause |
| Objective Duration of tumor response (DOR) assessed by the investigator | 24 months | Defined as the time from the first documented objective response to tumor recurrence or death from any cause during the study period as determined by the investigator according to RECIST 1.1 criteria, whichever occurs first |
| Duration of liver-specific DOR assessed by the investigator | 24 months | Defined as the time from the first documented liver objective remission to liver recurrence or death from any cause during the study period as determined by the investigator according to liver-specific RECIST 1.1 criteria, whichever occurs first |
| ORR assessed by the investigator | 24 months | Defined as the percentage of subjects with complete or partial tumor response as determined by the investigator according to RECIST 1.1 criteria |
Countries
China
Contacts
Primary ContactHui Wen, B.S.
Backup Contactxixi Hu, MS
Outcome results
None listed